Transplant Cell Ther. 2026 Oct;32(10):1252.e1-1252.e12. doi: 10.1016/j.jtct.2026.05.035. Epub 2026 Jun 13.
Ugo Chartral, Mony Fahd, Emma Gasperment, Charlotte Calvo, Martin Castelle, Elvira Duchesne, Aurélie Gabrion, Cécile Roudaut, Chloé Mollet, Brigitte Ternaux, Maxime Bouabdelli, Eden Schwartz, François Lefrère, Despina Moshous, Vincent Barlogis, Anne Charlotte Teyssier 8, Boris Calmels, Clemence Demerle, Anne-Line Chateau, Nimrod Buchbinder, Cécile Renard, Marie Ouachée, Cécile Pochon, Virginie Gandemer, Fanny Rialland, Catherine Paillard, Felipe Suarez , Jean-Hugues Dalle, Bénédicte Bruno, Elisa Magrin, Bénédicte Neven, Marina Cavazzana, Jean Sébastien Diana
Abstract
TCRαβ/CD19 depletion enables mismatched and haploidentical hematopoietic stem cell transplantation (HSCT) without the use of a post-transplant alkylating agent and is particularly relevant for pediatric nonmalignant disorders. However, the complexity of graft engineering limits its availability to specialized centers. Indeed, implementing such a process and obtaining regulatory approval are resource-intensive endeavors that require sufficient patient volume. To address these limitations, we established a centralized platform for the real-time nationwide distribution of fresh TCRα/β/CD19-depleted grafts in France, prioritizing bringing the cells to the patients, rather than the patients to the cells. This study aimed to evaluate the feasibility and challenges of this unique model of centralized, nationwide manufacturing of fresh TCRαβ/CD19-depleted grafts. In this retrospective cohort study (2014 to 2025), after on-site or off-site collections, all haploidentical or mismatched unrelated donors that underwent TCRα/β/CD19 depletion were manufactured at a single academic facility and delivered to nationwide transplant centers. Manufacturing performance, product compliance, logistics (vein-to-vein and delivery times), and early hematologic recovery were analyzed and compared for 10 transplant centers. A total of 55 products were distributed after undergoing TCRα/β/CD19 depletion for Inborn Errors of Immunity (n = 36), DNA repair/bone marrow failure (n = 15), and malignancies (n = 4). Despite significant heterogeneity in starting apheresis materials across different collection centers, manufacturing performance was robust and reliable, with comparable CD34+ recovery, TCRαβ, and CD19 depletion efficacy between on-site and off-site collections. Infused CD34 dose was similar between on-site and off-site apheresis (9.81 × 106/kg versus 9.91 × 106/kg), and TCRα/β doses were 5 in 96% of products. Vein-to-vein time met the
Keywords: Graft engineering; In vitro depletion; Mismatched donor; Nonmalignant disorders; Pediatric.
Copyright © 2026 The Authors. Published by Elsevier Inc. All rights reserved.
